LLS names Social Worker of the Year for 2010
The Leukemia & Lymphoma Society (LLS) has named Mary Ann Bassham, M.S.S.W., L.C.S.W., of the University of Texas M.D. Anderson Cancer Center in Houston the 2010 LLS Hematology-Oncology Social Worker of the Year. She will receive the award at the annual Association of Oncology Social Work (AOSW) conference in Phoenix, AZ. on May 12.
A Senior Social Work Counselor, Bassham's career spans 42 years, the last 20 of which have been spent at the renowned cancer center in Houston, most recently providing social services to patients in Lymphoma/Myeloma Clinic.
"I am honored and truly touched to be named Social Worker of the Year," said Bassham, quoted from the LLS monthly newsletter. "I would like to thank AOSW and LLS for the amazing contributions they make in the field of oncology social work. We all share a common goal, and that is to provide quality support to our patients and families."
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
